BlossomHill Therapeutics

BlossomHill Therapeutics is a private, clinical-stage biotech company focused on developing intelligently designed small molecule drugs for oncology and autoimmune disorders. The company's pipeline is anchored by a first-in-class macrocyclic OMNI-EGFR inhibitor for NSCLC and new pan-KRAS inhibitor programs, indicating a focus on high-value, difficult-to-drug targets. With an $84 million financing round closed in late 2025, BlossomHill is well-capitalized to advance its clinical-stage assets, positioning it as an emerging player in the precision oncology and autoimmune therapy landscape.

Advanced medicinal chemistry and structure-based drug design platform focused on creating macrocyclic and other complex small molecules to drug challenging targets like EGFR and KRAS.

In EGFR NSCLC, BlossomHill competes with multiple generations of TKIs from AstraZeneca, Pfizer, and others, as well as newer exon 20 inhibitors. In KRAS, it faces pioneers like Amgen and Mirati (G12C), and numerous companies pursuing G12D and pan-KRAS strategies. Differentiation will require demonstrating superior clinical profiles through novel chemistry.